Glioblastoma Therapy in the Age of Molecular Medicine

Area of Science:

• Neuro-oncology
• Cancer immunotherapy
• Tumor microenvironment research

Background:

• Glioblastoma (GBM) is the most common and lethal primary malignant brain tumor.
• Current GBM treatments have seen limited progress in the last decade.
• Bevacizumab failed to show benefits in Phase III trials for newly diagnosed GBM.

Purpose of the Study:

• To review recent advancements in therapeutic strategies for glioblastoma.
• To highlight novel approaches focusing on the tumor microenvironment.
• To discuss emerging antiangiogenic and immunotherapeutic treatments for GBM.

Main Methods:

• Review of current scientific literature and clinical trial data.
• Analysis of preclinical research on glioblastoma biology.
• Focus on therapeutic targets within the tumor microenvironment.

Main Results:

• Limited success of bevacizumab necessitates new antiangiogenic drug development.
• Immunotherapeutic approaches like checkpoint inhibitors and CAR T-cells show promise.
• Infiltrating microglia, macrophages, and metabolic alterations are key areas of research.

Conclusions:

• The tumor microenvironment is a critical target for novel glioblastoma therapies.
• Combination therapies integrating immunotherapy and targeted agents are being explored.
• Further research into microglia, macrophages, and metabolic pathways is essential for developing effective GBM treatments.